financetom
Business
financetom
/
Business
/
ArcBest Q3 Non-GAAP Net Income, Revenue Decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ArcBest Q3 Non-GAAP Net Income, Revenue Decline
Nov 1, 2024 4:05 AM

06:43 AM EDT, 11/01/2024 (MT Newswires) -- ArcBest ( ARCB ) reported Q3 non-GAAP net income Friday of $1.64 per diluted share, down from $2.31 a year earlier.

Analysts polled by Capital IQ expected $1.85.

Revenue for the quarter ended Sept. 30 was $1.06 billion, down from $1.13 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.07 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Norwegian Cruise lifts profit forecast again after record ticket sales
Norwegian Cruise lifts profit forecast again after record ticket sales
Nov 3, 2024
(Reuters) - Norwegian Cruise Line Holdings ( NCLH ) on Thursday raised its annual profit forecast for a fourth time this year, encouraged by record third-quarter revenue and advance ticket sales. Cruise operators marked robust demand this quarter for their vacation experiences as consumer spending in the U.S. increased at its fastest pace in 1-1/2 years and inflation slowed sharply....
Ametek raises FY profit forecast on strong quarterly sales, EMG segment growth
Ametek raises FY profit forecast on strong quarterly sales, EMG segment growth
Nov 3, 2024
Oct 31 (Reuters) - Industrial technology solutions provider Ametek ( AME ) raised its full-year profit forecast on Thursday, as third-quarter sales exceeded expectations, due to strong performance in its electromechanical (EMG) segment. Ametek ( AME ) shares rose 3% in pre-market trading. The company now expects full-year profit per share to be between $6.77 and $6.82, after previously lowering...
BRIEF-Psyence Biomedical Announces Closing Of Previously Announced Acquisition Of Psyence Group'S Stake In Psylabs
BRIEF-Psyence Biomedical Announces Closing Of Previously Announced Acquisition Of Psyence Group'S Stake In Psylabs
Nov 3, 2024
Oct 31 (Reuters) - Psyence Biomedical Ltd ( PBM ): * PSYENCE BIOMEDICAL ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED ACQUISITION OF PSYENCE GROUP'S STAKE IN PSYLABS Source text: Further company coverage: ...
Appili Therapeutics Announces
Appili Therapeutics Announces "Alignment" with FDA on ATI-1801 Development Requirements
Nov 3, 2024
07:57 AM EDT, 10/31/2024 (MT Newswires) -- Appili Therapeutics ( APLIF ) on Thursday said the U.S. Food and Drug Administration (FDA) has provided positive feedback regarding the development strategy for ATI-1801, a topical antibiotic treatment for cutaneous leishmaniasis, a disfiguring skin infection. The regulator also agreed on the necessary registration package to support a New Drug Application (NDA). ATI-1801...
Copyright 2023-2026 - www.financetom.com All Rights Reserved